ArticleBlood advances2020
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- A systematic review of physical function tests as predictors of key clinical outcomes for adults with blood cancers.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Pooled it
- Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Pooled it
- Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101.Blood advances · 2022Trial
- A CHARMed life after HCT: health span beyond life span.Blood advances · 2026Article
- Assessing cognitive function in transplantation and chimeric antigen receptor t cell therapy recipients: Expert recommendations from the survivorship, aging and biobehavioral special interest groups of the American Society for Transplantation and Cellular Therapy.Transplantation and cellular therapy · 2025Review
- Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies.Yonago acta medica · 2025Review
- Article
- Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.Blood advances · 2025Observational
- Pattern of change and predictors of cognitive function in older adults receiving allogeneic hematopoietic cell transplantation using the Montreal cognitive assessment.Journal of cancer survivorship : research and practice · 2025Article
- Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old.Blood · 2025Review
- Frailty assessment and outpatient pre-habilitation for adults undergoing allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2025Article
- Role of Geriatric Assessment in Hematopoietic Stem Cell Transplant and Cellular Therapies.Current treatment options in oncology · 2025Review
- Review
- Allogeneic Transplantation for Older Adults.Advances in experimental medicine and biology · 2025Review
- Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies.Blood advances · 2024Article
- Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102.JCO oncology practice · 2024Article
- Transplantation and Cellular Therapy for Older Adults-The MSK Approach.Current hematologic malignancy reports · 2024Review
- Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.Transplantation and cellular therapy · 2024Article
- Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study.Haematologica · 2024Article
- Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care.Frontiers in immunology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 12 institutions in 1 country.
Funding
Abstract
Use of allogeneic hematopoietic cell transplantation (alloHCT) is increasing in older patients with hematologic malignancies. Studies suggest that geriatric assessment (GA), incorporating functional measures such as instrumental activities of daily living (IADL), delineates subtle age-related impairments that enhance risk-stratification. The objective of this multi-institutional retrospective study was to evaluate the prognostic utility of GA metrics collected pre-alloHCT. Eligibility criteria included age ≥50 and pre-alloHCT GA inclusive of at least IADL. Beyond IADL, additional geriatric metrics were collected where available and included Medical Outcomes Study Physical Health score (MOS-PH), Timed Up and Go (TUG), and cognition by Blessed Orientation Memory Concentration (BOMC). Three hundred thirty subjects were included, with a median age of 63 (range 50 to 77). Impairments were frequent: 36% had at least 1 IADL impairment; 14% had TUG ≥13.5 seconds; and 17% had cognitive impairment (BOMC ≥ 7). Median MOS-PH score was 80. IADL and age were not significantly associated with nonrelapse mortality (NRM) or overall survival (OS). In multivariate analysis, only impaired cognition and Hematopoietic Cell Transplant-Comorbidity Index score ≥3 showed an independent association with 1-year NRM (subdistribution hazard ratio [SHR], 2.36; P = .01; and SHR, 2.19; P = .009, respectively). Cognitive impairment independently conferred inferior 1-year OS (hazard ratio, 1.94; P = .01). In a preplanned subgroup analysis in 224 patients aged ≥60 years, cognitive impairment remained the sole GA metric predictive of NRM (2-year NRM: SHR, 2.72; P = .007). These data suggest that cognitive impairment elevates risk of post-alloHCT NRM in older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.